By Fineline Cube Huadong Medicine (SHE: 000963) announced that KIO015 — a novel, patented carboxymethyl chitosan solution for injection developed by its UK subsidiary Sinclair Pharma Limited — has obtained EU MDR CE certification under the trade name Kytogen Defend. The clearance marks regulatory entry into the European market for what the company describes as the world’s only medical aesthetic chitosan product combining volumization, skin texture improvement, and deep hydration in a single treatment.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Huadong Medicine (SHE: 000963), via UK subsidiary Sinclair Pharma Limited |
| Product | KIO015 (trade name: Kytogen Defend) |
| Product Class | Carboxymethyl chitosan solution for injection |
| Certification | EU MDR CE certification |
| Announcement Date | 10 Aug 2026 |
Product Profile & Technology
- Core Ingredient: KiOmedine CM‑chitosan, a highly purified polysaccharide synthesized via proprietary KiOmedine technology
- Administration: Mesotherapy
- Differentiation: Currently the world’s only medical aesthetic chitosan product capable of simultaneously delivering superficial volumization, skin texture improvement, and deep hydration, leveraging groundbreaking patented technology
- Mechanism & Benefits:
- Protects endogenous hyaluronic acid
- Mitigates oxidative stress in dermal cells
- Enhances skin moisture content, elasticity, and radiance
- Targets fine lines, dryness, and overall skin quality loss
- Antioxidant Effect: Kytogen Defend demonstrates free‑radical scavenging capabilities that protect extracellular matrix components from oxidative degradation — an antioxidant effect confirmed through in vitro studies
Licensing History
| Item | Detail |
|---|---|
| Date | September 2021 |
| Licensor | KiOmed Pharma SA (Belgium) |
| Licensee | Sinclair Pharma Limited (UK subsidiary of Huadong Medicine) |
| Scope | Exclusive rights to develop and commercialize KiOmedine chitosan medical aesthetic products across skin aesthetic applications |
| Territory | Global, excluding the United States |
In September 2021, Sinclair acquired exclusive rights from Belgium’s KiOmed Pharma SA to develop and commercialize KiOmedine chitosan medical aesthetic products across skin aesthetic applications globally, excluding the United States.
Market Impact & Outlook
- Regulatory Gateway: EU MDR CE certification — widely regarded as one of the most stringent regulatory pathways for medical devices — clears Kytogen Defend for commercial rollout across the European Economic Area under Sinclair’s established aesthetic distribution network.
- Category Creation: As the only medical aesthetic chitosan product with triple-action positioning (volumization + texture + hydration), Kytogen Defend sits outside the crowded hyaluronic acid filler category, potentially opening a differentiated niche in the skin booster segment.
- Pipeline Optionality: The 2021 exclusive license from KiOmed Pharma covers the broader KiOmedine chitosan platform globally (ex‑US), giving Sinclair and Huadong Medicine a portfolio runway beyond this first certified product.
- Strategic Fit: The certification strengthens Huadong Medicine’s international medical aesthetics footprint, complementing Sinclair’s existing portfolio and reinforcing the company’s positioning in the premium aesthetic injectables market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Kytogen Defend and the development of KiOmedine chitosan medical aesthetic products. Actual results may differ due to risks including market adoption, competitive dynamics, and regulatory developments.-Fineline Info & Tech